<DOC>
	<DOCNO>NCT02100371</DOCNO>
	<brief_summary>This extension study Protocol CA194002 allow 2 specific participant basal cell nevus syndrome CA194002 study Princess Margaret Cancer Centre still benefit study drug BMS-833923 continue receive study drug . This study continue evaluate safety tolerability BMS-833923 participant .</brief_summary>
	<brief_title>Study BMS-833923 Two Specific Patients With Basal Cell Nevus Syndrome</brief_title>
	<detailed_description>The purpose study evaluate safety tolerability BMS-833923 administer extension protocol subject basal cell nevus syndrome ( BCNS ) . This extension study Protocol CA194002 allow 2 specific participant BCNS CA194002 study Princess Margaret Cancer Centre still benefit study drug BMS-833923 , continue receive study drug . In open-label extension protocol , new subject recruit . The two BCNS subject Protocol CA194002 ( subject CA194002-1-14 CA194002-1-25 ) continue receive BMS-833923 dose schedule administer CA194002 fulfil protocol criterion discontinuation . These patient receive different dos : one 60mg every 2 week , receive 300mg daily . This study continue evaluate safety tolerability BMS-833923 participant .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nevus</mesh_term>
	<mesh_term>Nevus , Pigmented</mesh_term>
	<mesh_term>Basal Cell Nevus Syndrome</mesh_term>
	<criteria>Signed consent Two specific study participant enrol protocol CA194002 Princess Margaret Cancer Centre remain BMS833923 time study entry Women , age 18 year Agree use method prevent pregnancy , pregnant breastfeed Known symptomatic brain metastasis A serious uncontrolled medical disorder active infection , would impair ability patient receive protocol therapy Gastrointestinal disease surgery could impact absorption study drug Inability swallow oral medication Inability venipunctured and/or tolerate venous access Uncontrolled significant cardiovascular Any medical , psychiatric and/or social reason Have HIV , HepB , HepC Exposure immunosuppressants immunotherapy concurrently study treatment 3 month Acceptable physical laboratory test finding History allergy compound chemicallyrelated</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>BMS-833923</keyword>
	<keyword>CA194002</keyword>
</DOC>